Biomarker Analyses in CLEOPATRA


Biomarker Analyses in CLEOPATRA
Slides from a presentation at SABCS 2012 and transcribed comments from a recent interview with José Baselga, MD, PhD (3/9/13)
Baselga J et al. Biomarker analyses in CLEOPATRA: A Phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 2012;Abstract S5-1.

Dr Blackwell is Professor of Medicine and Director of the Breast Cancer Program at Duke Cancer Institute in Durham, North Carolina.